NTRK1 and cancer: In addition, several pathways are involved in cancer cell resistance to BET inhibitors, including the activation of receptor tyrosine kinases (RTKs), JAK-STAT, phosphatidylinositol 3-kinase (PI3K), AKT/mTOR, and MAPK/ERK pathways (32).